DE602005005843T2 - 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie - Google Patents

4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie Download PDF

Info

Publication number
DE602005005843T2
DE602005005843T2 DE602005005843T DE602005005843T DE602005005843T2 DE 602005005843 T2 DE602005005843 T2 DE 602005005843T2 DE 602005005843 T DE602005005843 T DE 602005005843T DE 602005005843 T DE602005005843 T DE 602005005843T DE 602005005843 T2 DE602005005843 T2 DE 602005005843T2
Authority
DE
Germany
Prior art keywords
methoxyphenyl
dichloro
amino
quinolinecarbonitrile
ynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005005843T
Other languages
German (de)
English (en)
Other versions
DE602005005843D1 (de
Inventor
Diane Harris New City BOSCHELLI
Margaret Narberth ZALESKA
Ana Carolina Olanta BARRIOS-SOSA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of DE602005005843D1 publication Critical patent/DE602005005843D1/de
Application granted granted Critical
Publication of DE602005005843T2 publication Critical patent/DE602005005843T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
DE602005005843T 2004-10-22 2005-10-21 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie Expired - Lifetime DE602005005843T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62128004P 2004-10-22 2004-10-22
US621280P 2004-10-22
PCT/US2005/037839 WO2006047262A1 (en) 2004-10-22 2005-10-21 4 [(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (2)

Publication Number Publication Date
DE602005005843D1 DE602005005843D1 (de) 2008-05-15
DE602005005843T2 true DE602005005843T2 (de) 2009-05-14

Family

ID=35784691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005005843T Expired - Lifetime DE602005005843T2 (de) 2004-10-22 2005-10-21 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie

Country Status (23)

Country Link
US (1) US20060116375A1 (enExample)
EP (1) EP1802581B1 (enExample)
JP (1) JP2008517924A (enExample)
KR (1) KR20070085413A (enExample)
CN (1) CN101044117A (enExample)
AT (1) ATE391122T1 (enExample)
AU (1) AU2005299822A1 (enExample)
BR (1) BRPI0516995A (enExample)
CA (1) CA2581807A1 (enExample)
CR (1) CR9072A (enExample)
DE (1) DE602005005843T2 (enExample)
DK (1) DK1802581T3 (enExample)
EC (1) ECSP077385A (enExample)
ES (1) ES2303287T3 (enExample)
IL (1) IL182547A0 (enExample)
MX (1) MX2007004833A (enExample)
NO (1) NO20071708L (enExample)
PL (1) PL1802581T3 (enExample)
PT (1) PT1802581E (enExample)
RU (1) RU2007111704A (enExample)
SI (1) SI1802581T1 (enExample)
WO (1) WO2006047262A1 (enExample)
ZA (1) ZA200703275B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
WO2014086284A1 (zh) * 2012-12-04 2014-06-12 上海医药集团股份有限公司 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN114436851B (zh) * 2022-01-17 2023-08-22 常州大学 一种n,n-二甲基苄胺及其衍生物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
TW200423938A (en) * 2003-02-21 2004-11-16 Wyeth Corp 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Also Published As

Publication number Publication date
CN101044117A (zh) 2007-09-26
NO20071708L (no) 2007-07-13
MX2007004833A (es) 2007-05-16
CR9072A (es) 2007-09-07
JP2008517924A (ja) 2008-05-29
US20060116375A1 (en) 2006-06-01
WO2006047262A1 (en) 2006-05-04
ATE391122T1 (de) 2008-04-15
KR20070085413A (ko) 2007-08-27
DK1802581T3 (da) 2008-06-30
EP1802581A1 (en) 2007-07-04
AU2005299822A1 (en) 2006-05-04
CA2581807A1 (en) 2006-05-04
DE602005005843D1 (de) 2008-05-15
ES2303287T3 (es) 2008-08-01
HK1104555A1 (en) 2008-01-18
SI1802581T1 (sl) 2008-08-31
RU2007111704A (ru) 2008-11-27
IL182547A0 (en) 2007-09-20
EP1802581B1 (en) 2008-04-02
PT1802581E (pt) 2008-06-03
PL1802581T3 (pl) 2008-09-30
ZA200703275B (en) 2008-08-27
BRPI0516995A (pt) 2008-09-30
ECSP077385A (es) 2007-05-30

Similar Documents

Publication Publication Date Title
DE69724108T2 (de) Isochinolinderivate und arzneimittel
DE69613240T2 (de) N-aminoalkylfluorencarboxamide, neue klasse von dopaminerezeptor subtype spezifische liganden
DE60103390T2 (de) Diazepinderivate oder deren salze
DE3876400T2 (de) Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen.
EP1216246B1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE60202958T2 (de) Stabiles polymorph von flibanserin, industrielles verfahren zu dessen herstellung und dessen verwendung zur herstellung von medikamenten
EP1140898B1 (de) Amid- und harnstoffderivate als 5-ht reuptakeinhibitoren und als 5-ht1b/1d liganden
DE69533194T2 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
DE10202468A1 (de) Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung
DE69027180T2 (de) 4-Acylaminopyridin-Derivate
DD155991A5 (de) Verfahren zur herstellung von imidazolin-derivaten
DE69606165T2 (de) Bizyclische isothioharnstoff-derivate mit therapeutischer wirkung
DE4430091A1 (de) Verwendung von N-substituierten Phenothiazinen
DE60104130T2 (de) 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate
EP1581506B1 (de) Verwendung von 2-amino-2h-chinazolin-derivaten zur herstellung von therapeutischen mitteln
DE69232484T2 (de) Hydroisochinolinderivate
DE602005005843T2 (de) 4 ä(2,4-dichloro-5-methoxyphenyl)aminoü-6-alkoxy-7-ethynyl-3-chinolincarbonitrile zur behandlung von ischämie
DD281596A5 (de) Verfahren zur hersteung antiarrhytmischer mittel
EP1317430B1 (de) (2-azabicyclo [2.2.1]hept-7-yl)methanol-derivate als nikotinische acetylcholinrezeptor agonisten
DE3781483T2 (de) Pharmazeutische zusammensetzung zum schutz von gehirnzellen.
DE69424816T2 (de) N-Benzylpiperazinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende Zusammensetzungen
EP0496274A1 (de) Tricyclisches Pyridonderivat
DE60304327T2 (de) 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINOi4,5-BöINDOLACETAMIDDERIVATE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE THERAPEUTISCHE VERWENDUNG
DE60204046T2 (de) N-heterocyclylhydrazide als neurotrophe mittel
DE69026936T2 (de) 5-aminocarbonyl-5h-dibenzo-a,d]cyclohepten-5,10-imine zur behandlung von epilepsie und kokainsucht

Legal Events

Date Code Title Description
8364 No opposition during term of opposition